Showing results (1191-1200 of 1,344) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|November 18, 2009
Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cellsA K Maiti
The Pharmacogenomics Journal|November 4, 2009
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapyS P R Romaine, K M Bailey, A S Hall, et al.
The Pharmacogenomics Journal|September 17, 2014
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral densityC Wang, H Zheng, J-W He, et al.
The Pharmacogenomics Journal|September 2, 2015
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentY Shirasaka, A S Chaudhry, M McDonald, et al.
The Pharmacogenomics Journal|September 2, 2015
Genome-wide association study on antipsychotic-induced weight gain in the CATIE sampleE J Brandl, A K Tiwari, C C Zai, et al.
The Pharmacogenomics Journal|August 2, 2017
Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomesG S Hwang, R Bhat, R D Crutchley, et al.
The Pharmacogenomics Journal|August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesC F Spraggs, L R Parham, L P Briley, et al.
The Pharmacogenomics Journal|July 19, 2017
Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiologyA A Seyerle, C M Sitlani, R Noordam, et al.
The Pharmacogenomics Journal|December 16, 2015
Impact of GSTM1, GSTT1 and GSTP1 gene polymorphism and risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulationH O Singh, S Lata, M Angadi, et al.
The Pharmacogenomics Journal|December 9, 2015
Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trialK L Ellis, Y Zhou, L Rodriguez-Murillo, et al.
Pageof 135